12,053 Shares in Ascendis Pharma A/S $ASND Purchased by Point72 Europe London LLP

Key Points

• Point72 Europe London LLP has acquired a new position in Ascendis Pharma A/S, purchasing 12,053 shares valued at approximately $1.88 million.
• Ascendis Pharma reported a quarterly revenue of $216.28 million, surpassing the consensus estimate of $163.17 million, with an EPS of ($0.93), beating estimates by $0.49.
• A majority of analysts have rated Ascendis Pharma with a Buy rating and an average price target of $243.36, with recent targets reaching as high as $295.00.

Point72 Europe London LLP purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,053 shares of the biotechnology company's stock, valued at approximately $1,879,000.

Several other large investors also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its position in Ascendis Pharma A/S by 12.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after buying an additional 328,278 shares during the last quarter. Vestal Point Capital LP lifted its position in Ascendis Pharma A/S by 108.0% during the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after purchasing an additional 270,000 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after purchasing an additional 193,688 shares during the last quarter. Soleus Capital Management L.P. purchased a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $19,824,000. Finally, GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 15,593.0% in the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock worth $142,600,000 after purchasing an additional 90,907 shares during the last quarter.

Ascendis Pharma A/S Stock Up 0.4%

NASDAQ:ASND traded up $0.86 during mid-day trading on Wednesday, hitting $200.02. 415,545 shares of the company traded hands, compared to its average volume of 525,297. The stock's fifty day moving average price is $181.50 and its 200-day moving average price is $167.16. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $203.59. The firm has a market cap of $12.24 billion, a price-to-earnings ratio of -38.76 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of research analyst reports. Oppenheimer restated an "outperform" rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Wells Fargo & Company reiterated an "overweight" rating and set a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Wedbush boosted their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Finally, Morgan Stanley began coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price target on the stock. Fifteen analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $244.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.